Paroxysmal Atrial Fibrillation
Conditions
Interventions
Experimental Group (TCM formula + standard therapy):QLTLDJF (200mL, bid) + guideline-based Western treatment (anticoagulation, rate/rhythm control)
Control Group (Standard therapy):Guideline-based Western treatment only (anticoagulation, rate/rhythm control), without Chinese herbal preparations
Sponsors
Beijing University of Traditional Chinese Medicine Dongzhimen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: (1) Age 18-80; (2) Diagnosis of paroxysmal AF with Qi-Yin deficiency and phlegm-stasis syndrome; (3) EHRA class 2-3; (4) Signed informed consent.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: (1) Valvular AF; (2) Hyperthyroidism-induced AF; (3) Planned/prior pacemaker implantation or bradyarrhythmia; (4) NYHA class IV or LVEF=40%; Left atrial diameter>50mm; Moderate-severe LVH (>15mm); (5) Acute coronary syndrome, recent stroke (<3mo), bleeding disorders, left atrial thrombus, severe hepatic/renal dysfunction (ALT=3×ULN or eGFR<50ml/min/1.73m²); (6) Hypersensitivity to study drugs; (7) Pregnancy/lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Atrial fibrillation burden; | — |
Secondary
| Measure | Time frame |
|---|---|
| syndrome in traditional Chinese medicine;European Heart Rhythm Association Symptom Scale for Atrial Fibrillation;Peripheral Blood Secreted Phosphoprotein 1;Interleukin-6;Tumor Necrosis Factor-a;Interleukin-1ß;Monocyte Chemoattractant Protein-1;Atrial Fibrillation Effect on QualiTy-of-life Questionnaire; | — |
Countries
China
Contacts
Public ContactWang Xian
Beijing University of Chinese Medicine Dongzhimen Hospital
Outcome results
None listed